Patent expirations won't hold back success of some drug firms

11/18/2003 | Bloomberg Businessweek

Although many drug firms are facing patent expirations next year, investors are bullish on several companies. For example, Pfizer is favored among investors based on anticipated 2004 sales of its recently approved drug for congestive heart failure. Abbott recently launched Humira, a rheumatoid arthritis drug that could be a hit, while Wyeth's lack of patent expirations could outweigh its weak pipeline.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD